Insulin-like Growth Factor 1

Insulin-like Growth Factor 1 (IGF-1) is a peptide hormone primarily produced in the liver and plays a crucial role in growth and development. Researchers primarily study IGF-1 for its involvement in various physiological processes, including glucose metabolism, muscle hypertrophy, and cardiac adaptation to stress. Key findings indicate that IGF-1 signaling is linked to the regulation of glucose uptake in colorectal cancer cells and is essential for skeletal muscle protein synthesis and regeneration. Additionally, studies suggest that IGF-1 levels can be influenced by gut microbiota, which may modulate host growth and health. Current research continues to explore the multifaceted roles of IGF-1 in health and disease, highlighting its clinical relevance in conditions such as metabolic syndrome and muscle atrophy.

Insulin-like Growth Factor 1 (IGF-1), also known as Somatomedin C or Mecasermin in its synthetic form, is an endogenous peptide hormone primarily produced in the liver under the stimulation of growth hormone (GH). It belongs to the class of growth factors and plays a crucial role in growth and development. IGF-1 is structurally similar to insulin and is involved in various physiological processes. Researchers have observed that IGF-1 is pivotal in regulating growth and development, particularly in skeletal muscle hypertrophy and atrophy, as well as in glucose metabolism. It has been studied extensively in the context of cancer, particularly colorectal cancer, where it is implicated in glucose metabolism and the Warburg effect. Additionally, IGF-1 is involved in cardiac growth and adaptation to stress, as well as in interactions with gut microbiota that influence host development. IGF-1 exerts its effects through binding to the IGF-1 receptor (IGF-1R), activating intracellular signaling pathways such as PI3K/Akt/mTOR and MAPK/ERK, which are crucial for its anabolic and anti-catabolic effects. The modulation of these pathways influences protein synthesis, glucose uptake, and cell survival. The pharmacokinetic properties of IGF-1 include a circulating half-life of approximately 12-15 hours when bound to IGF-binding proteins, which extend its half-life and bioavailability. IGF-1 is used clinically in specific growth failure conditions and is regulated as a prescription medication. It is also monitored in sports for potential misuse as a performance-enhancing agent, with strict anti-doping regulations in place.

IGF-1 acts primarily through the IGF-1 receptor (IGF-1R), activating the PI3K/Akt/mTOR and MAPK/ERK pathways. This activation leads to increased protein synthesis, cell growth, and survival, while inhibiting apoptosis and catabolic processes.

Insulin-like Growth Factor 1 (IGF-1) primarily exerts its effects through the IGF-1 receptor (IGF-1R), activating downstream signaling pathways such as the PI3K/Akt/mTOR and Raf/MAPK pathways. This signaling promotes anabolic processes like protein synthesis in skeletal muscle and enhances glucose uptake by activating glucose transporters (e.g., GLUT1), while also inhibiting catabolic processes by suppressing FoxO transcription factors and the ubiquitin-proteasome system. Although the precise mechanisms linking IGF-1 to metabolic syndrome and cancer phenotypes, such as the Warburg effect, remain incompletely understood, its role in modulating cellular growth, metabolism, and regeneration is well established.

Current evidence is limited regarding the specific mechanisms by which IGF-1 signaling interacts with metabolic syndrome and colorectal cancer, particularly in the context of the Warburg effect and its regulation of glucose metabolism. Further research is needed to elucidate the role of IGF-1 in muscle atrophy and hypertrophy, especially the contributions of autophagy and miRNA regulation in various chronic disease states. Additionally, the relationship between gut microbiota and IGF-1 synthesis requires further investigation, particularly through larger longitudinal studies that explore the impact of specific microbiota on IGF-1 levels across diverse populations.